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Introduction
Prostate cancer has been the sixth most common
malignancy and the seventh leading cause of can-
cer deaths in Taiwanese males for more than 5 years.
More than 2,000 men are diagnosed annually with
prostate cancer, of which approximately 750 die [1].
There has been an obvious increase in the annual
detection rate in Taiwan since the late 1990s, as
well as in other Asian countries [2,3]. Despite the
increase in detection rates, tumors have not been
detected at an earlier stage [4]. In contrast, prostate
cancer remains the most common malignancy in
Western males and second leading cause of cancer
deaths [5]. Given that the majority of biopsy proto-
cols are reported and conducted in countries with
a high incidence of prostate cancer, it is worth dis-
cussing the optimal strategy for those countries
with a rising incidence of the disease [6].
As in general medical ultrasound, transrectal ultra-
sound (TRUS) is a continuously developing field;
Watanabe et al [7] first introduced TRUS as a clinical
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application for evaluating the prostate [8–10].
Fewer prostate cancers can be detected by lesion-
directed biopsy using two-dimensional (2-D) gray-
scale imaging compared with systematic random
biopsy [8]; therefore, the strategy of systematic ran-
dom biopsy with reasonable biopsy cores has re-
placed the protocol of targeting hypoechoic lesions
and has become the mainstay in prostate-specific
antigen (PSA) screening [9]. Nevertheless, follow-
ing advances in ultrasound technology machines,
particularly the progress in computing and Doppler
techniques, sonomorphologic lesions and/or asso-
ciated increased vascularity are still worthy of
attention [6,10,11].
In this article, we briefly summarize our experi-
ence and the problems we have encountered using
TRUS in diagnosing prostate cancer at National
Cheng Kung University Hospital (NCKUH). We 
review the progress in biopsy protocols for both
targeted lesion and systematic random biopsy 
protocols.
The NCKUH Experience
TRUS has been applied at NCKUH for the detection
of prostate cancer since the 1990s using the follow-
ing biopsy strategy: three to five lesion-targeted
biopsy cores are taken in the case of any sonomor-
phologically suspicious lesion over the peripheral
zone; otherwise, 3 to 5 biopsy cores are obtained
randomly on the basis of transverse examination
of prostate halves [6]. The role of TRUS is to ensure
accurate sampling of prostate tissue for histologic
examination in men at higher risk of harboring can-
cer, particularly those with an elevated PSA level and
abnormal digital rectal examination (DRE). Both PSA
and DRE aid in the detection of prostate cancer
[6,12,13]. Data from a small cohort of 90 patients
who received prostate biopsy revealed that among
59 patients with abnormal DRE prostate cancer
was detected not only in hypoechoic lesions (n =
10; 17.8%), but also in an isoechoic lesion (n = 1;
1.8%) and in diffusely heterogeneous lesions (n = 7;
12.5%). In contrast, only two prostate cancers were
detected in hypoechoic lesions (n=2; 5.9%) among
34 patients with normal DRE [12]. The results of 
a 5-year cohort study of 518 patients conducted
between 1998 and 2002 showed that the cancer
detection rate was superior for lesion-directed biopsy
when compared with that for random biopsy, re-
gardless of PSA levels. Nevertheless, approximately
40 patients would have been missed if lesion-
directed biopsy alone had been performed [6]. Only
25 of 207 prostate cancers (12%) were detected
for cases with a PSA level of less than 10.0 ng/mL.
These results served as a warning that some pros-
tate cancers would be missed using such a biopsy
strategy, particularly for those with PSA of less than
10.0ng/mL. Therefore, we were prompted to con-
sider the most effective strategy for enhancing the
detection of early prostate cancer in patients with
PSA of less than 10.0 ng/mL.
Biopsy Protocols
Targeted hypoechoic or sonomorphologic
lesions
Grayscale 2-D imaging in the axial and longitudinal
planes remains the main method of obtaining the
best view of the anatomic delineation of structures
around or within the prostate gland, such as the sur-
rounding fat tissue, rectum, neurovascular bundles,
seminal vesicles, and venous plexus, as well as the
transition, central and peripheral zones [14].
Even so, it is only possible to obtain partial visu-
alization of prostate cancer, meaning that limitations
are encountered in obtaining accurate staging sta-
tus [15], hypoechoic lesions are traditionally thought
to be the main presentation of prostate cancer
(Fig. 1); over the past two decades, these lesions
have been targeted at biopsy [16]. The hypoechoic
appearance is thought to reflect increased micro-
vascularity density [17]. In the PSA era, the likeli-
hood of a hypoechoic lesion being diagnosed as
prostate cancer declined from 17–57% to 9% fol-
lowing the increased use of random biopsy cores
[15,18,19]. Schroder et al reported a positive pre-
dictive value of DRE and TRUS of only 9.7% in a
Y.S. Tsai, C.H. Chen, Y.H. Lin, et al
184 J Med Ultrasound 2007 • Vol 15 • No 3
large cohort of 9,211 patients with PSA of less than
4.0 ng/mL [20]. It is, therefore, difficult to visualize
prostate cancer from grayscale 2-D images solely
by hypoechoic lesion. In general, the accuracy rate
in cancer detection ranges from 41 to 74% [21].
Targeted Doppler-enhanced lesions
Over the past two decades, Doppler techniques
have been applied in perfusion studies of the pros-
tate gland [22,23]. Until recently, three Doppler-
associated techniques were available for prostate
ultrasound: color Doppler, power Doppler, and
contrast-enhanced techniques [24–26].
In simple terms, the prostaticovesical arteries, aris-
ing from the internal iliac arteries, provide the blood
supply to the human prostate. The prostaticovesical
arteries divide into two branches: the prostatic artery
and the inferior vesical artery. The prostatic artery,
which is either single or composed of four to five
branches, reaches the prostate gland on its antero-
lateral surface and gives rise to two groups of
intraprostatic arteries: the urethral arteries and the
TRUS for Prostate Cancer
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Fig. 1. Lesions sonomorphologically suspicious for cancer, confirmed by histologic examination. (A) A 72-year-old man received
bilateral sextant biopsies because of an elevated prostate-specific antigen (PSA) level (7.19 ng/mL). Pathologic examination revealed
prostatic adenocarcinoma in all 6 cores (Gleason score, 3 + 3; right-sided cores, 50% of area; left-sided cores, 30% of area). (B)
A 73-year-old man had lesion-directed prostate biopsy in the left peripheral zone and random biopsy on the right side because of an
elevated PSA level (11.29 ng/mL). Pathologic examination revealed prostatic adenocarcinoma solely from the left isoechoic lesion
(Gleason score, 4 + 4; 40% of area). (C) A 69-year-old man underwent 10-core prostate biopsy (including one core from a hypo-
echoic lesion) because of an elevated PSA level (10.21 ng/mL). Pathologic examination of the targeted hypoechoic lesion showed
prostatic adenocarcinoma (Gleason score, 4 + 3; 80% of area), and one core from the other side showed microfocal prostate can-
cer (Gleason score, 2 + 2; 5% of area). (D) A 53-year-old man had bilateral sextant biopsy because of an elevated PSA level
(11.36 ng/mL). Transrectal ultrasound found only one suspicious hypoechoic lesion in the right peripheral zone. Pathologic exami-
nation revealed prostatic adenocarcinoma on the right side (Gleason score, 3 + 2; 20% of area) and prostatitis on the left side.
capsular arteries. These arteries are distributed in a
moderately regular manner throughout the prostate
[27]. Because prostate cancer tends to have an
increased density of capillaries compared with healthy
prostatic tissue due to neovascularization [28], sev-
eral phenomena are viewed as significant, including
the presence of hypervascularity, a high degree of
flow, left–right asymmetry, and mass effect changes
(a gap in perfusion around the lesion due to com-
pression of the vessels by the pressure of the tumor
mass) on the vessel structure [24–26,29].
Although some technical differences exist among
these three Doppler-related perfusion imaging tech-
niques, the accuracy rates in cancer detection are
reported to be similar (color Doppler, 53–
84%; power Doppler, 40–83%; contrast-enhancing
Doppler, 40–91%) [21]. Color Doppler imaging
measures blood flow velocity and direction, while
power Doppler uses the Doppler signal amplitude
rather than velocity or flow direction. Power Doppler
shows greater sensitivity in depicting blood flow
and the number, course, and continuity of vessels,
and is more able to visualize smaller vessels and
vessels with lower flow velocity than is the case with
color Doppler [30].
The vascular anatomy of the normal prostate, as
displayed by power Doppler, demonstrates a repro-
ducible and symmetric flow pattern [30]. Three
flow patterns are recognized as signs of prostate
cancer: increased flow within a lesion, increased
flow surrounding a lesion, and asymmetric flow in
comparison to adjacent tissue or contralateral
areas (Fig. 2) [31].
In a cohort of 579 patients with PSA of more
than 3.5 ng/mL, 20 of 39 patients had T1c cancer
that was invisible with power Doppler sonography
[32]. These data reflect limited performance in the
detection of early prostate cancer. In fact, power
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Fig. 2. Doppler-enhanced lesions confirmed by histologic examination. (A, B, C) Case 1: a 57-year-old man received bilateral
biopsies (right side, targeted biopsy [3 cores]; left side, random biopsy [5 cores]) because of an elevated prostate-specific antigen
(PSA) level of 14.85 ng/mL. Pathologic examination revealed prostatic adenocarcinoma solely from the targeted hypoechoic lesion
that had Doppler enhancement (Gleason score, 4 + 3; 80% of area). (D, E, F) Case 2: a 67-year-old man received bilateral biopsies
(right side, targeted biopsy [2 cores]; left side, random biopsy [4 cores]) because of an elevated PSA level of 27.1 ng/mL.
Pathologic examination revealed prostatic adenocarcinoma on both sides (Gleason score, 4 + 3, bilateral; right, 80% of area; left,
15% of area). In both of these cases, three flow patterns categorized as a sign of prostate cancer were visible. These signs include
increased flow within a lesion, increased flow surrounding a lesion, and asymmetric flow relative to adjacent tissue or contralateral
areas (A, D: 2-D grayscale; B, E: color Doppler; C, F: power Doppler).
Doppler ultrasound plays the dominant role in
optimizing the number of useful biopsy cores and
avoiding unnecessary cores in advanced disease
[32,33].
Because the contrast agents (microbubbles) 
remain within the vessels, the difference in acoustic
impedance between microbubbles and adjacent
tissue results in higher reflective interfaces. There-
fore, these microbubbles are optimal for real-time
visualization of the vasculature [34]. Contrast-
enhanced Doppler techniques have become increas-
ingly sensitive in perfusion imaging [26,35]. In a
cohort of 85 patients, Roy et al compared the diag-
nostic performance of color Doppler images with
and without contrast enhancement [26], reporting
that contrast-enhanced color Doppler had higher
sensitivity (93%) than unenhanced color Doppler
(54%), while specificity increased from 79 to 87%
for enhanced imaging [26]. Nevertheless, it is worth-
while to explore the diagnostic value of contrast-
enhanced Doppler techniques in early prostate
cancer.
Three-dimensional (3-D) images
3-D technique has been applied to ultrasound of the
prostate [36,37]. Theoretically, in comparison with
2-D TRUS, which is a projection of a single image,
3-D TRUS produces a series of sequentially overlaid
images, with the final result being an image of
greater resolution and quality. Despite this benefit,
the image acquired using a standard 3-D endorectal
transducer uses the same gray scale as conven-
tional 2-D TRUS. The diagnosis of prostate cancer is
the same as for conventional 2-D TRUS [38], relying
entirely on the visibility of prostate cancer lesions.
Nevertheless, 3-D reconstructions in conventional
TRUS imaging are superior to 2-D imaging in stag-
ing localized prostate cancer. Garg et al, in a small
cohort of 36 cases of newly diagnosed localized
prostate cancer, first reported that 3-D TRUS had an
overall staging accuracy comparable to 2-D TRUS
(94% vs. 72%; p<0.05) [36]. Recently, Mitterberger
et al reported in a larger cohort of 180 patients that
3D-TRUS identified extracapsular extension with
an overall accuracy of 92% and seminal vesicle
invasion with an overall accuracy of 91% [39].
Similarly, other modalities, such as power Doppler
with or without contrast-enhanced images, might
serve to augment the cancer detection rate of 3-D
TRUS [40].
Systematic biopsy protocols
Following the introduction of the systematic sex-
tant biopsy method by Hodge et al in the detec-
tion of prostate cancer [8], systematic random
biopsy became a mainstream technique following
several modifications, including the optimal num-
ber of biopsy cores and the location [9,41]. The
systematic random biopsy method differs from
imaging-based techniques that target hypoechoic
or Doppler-enhancing lesions, because it does not
target any sonomorphologically suspicious lesions
from TRUS; instead, it uses standard locations from
which biopsies are taken. As reported by Hodge 
et al, the prostate is bilaterally divided into three
regions (apex, mid-gland, and base), all of which are
systematically biopsied once [8]. However, numer-
ous studies demonstrated that further biopsy cores
from additional bilateral transition zone, apex, or
lateral regions result in higher detection rates, and
data from the early 1990s demonstrated that a 
significant number of cancers were being missed
using the six-core approach, particularly in larger
glands [41–43]. For example, Eskicorapci et al re-
ported in a cohort of 303 patients that the cancer
detection rate of the 10-core biopsy strategy was
31% (94/303), compared with 23.1% (70/303)
for the sextant biopsy strategy, in which there were
3 (0.9%) serious complications requiring hospital-
ization because of infections [42]. Thus, one par-
ticular question was frequently asked: how many
biopsy cores are sufficient for cancer detection when
the systematic random biopsy strategy is selected
[44]? Currently, a systematic standard biopsy ses-
sion may encompass any number of biopsy cores,
with 10–12 being used most frequently [42,43],
detecting 31% more cancers (95% confidence 
interval, 25–37%) than sextant biopsy when tak-
ing additional laterally directed cores [9,45]. The
severity of biopsy-related pain and the number of
TRUS for Prostate Cancer
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post-biopsy complications are possibly the same
for both systematic sextant and 12-core extended
biopsy [9,46,47], and increased sampling of the
prostate does not increase the detection of poten-
tially insignificant tumors [42,48]. Therefore, TRUS
has become important in obtaining the accurate
location of prostate tissue sampling in a systematic
random method. Despite that taking more than
12 cores adds no significant benefit [9], a 24-core
saturation prostate biopsy protocol was conducted
and investigated under local anesthesia [49]; how-
ever, the role of this technique remains to be
defined. Sampling location is also a key point in
maximizing the cancer detection rate, particularly
in the peripheral zone [50]. Philip et al, in a cohort
of 241 patients with persistent elevated age-
specific PSA and initial negative biopsy, reported
that the maximum cancer detection rates were
obtained from the peripheral apices, followed by
basal biopsies and parasagittal biopsies in repeat
12-core biopsy protocols [50].
Predictive models to provide optimal cores or
the probability of prostate cancer
Many factors potentially influence the cancer detec-
tion rate during prostate biopsy, including PSA level,
DRE findings, age, race, prostate volume, number
of biopsy cores, location, and the selected biopsy
strategy [6,8,9,12,51]. Conventionally, patients with
either an elevated PSA level or abnormal DRE have a
higher probability and a greater extent of prostate
cancer [6]. Because TRUS is not accurate in staging
prostate cancer [15], a standard sextant biopsy or
a lesser number of biopsy cores might be sufficient
for pathologic proof of malignancy in advanced or
even metastatic prostate cancer patients with a
strongly elevated level of PSA or hard prostate,
rather than an extended 12-core biopsy strategy.
To reduce unnecessary biopsy cores, previous authors
have investigated and reported a predictive model
for prostate biopsy concerned with the minimum
number of cores required to detect cancers with a
high degree of certainty [41,52]. Two determining
variables, age and prostate volume, can be used to
create a nomogram for determining the number of
biopsy cores necessary to ensure a 90% certainty of
cancer detection (e.g. the Vienna nomogram) [41,
53]. In a cohort of 834 Japanese patients, Suzuki et al
incorporated several clinical and laboratory factors,
including PSA, percentage of free PSA, prostate vol-
ume, and DRE findings, into a pre-biopsy nomogram
that can significantly improve the prediction of the
existence of prostate cancer compared with pre-
dictions based solely on these factors individually
[52]. Despite this advance, it is important to ask
whether such a nomogram would be effective in
countries with a low incidence, rising incidence, or
high incidence of prostate cancer [4,51].
Summary
The incidence and cancer deaths of prostate cancer
have been increasing over the past decade. Our ex-
perience in using our own biopsy strategy indicates
that most patients have a PSA level of greater than
10.0 ng/mL when diagnosed with prostate cancer.
The data also reveal that many patients are diag-
nosed with prostate cancer mainly from random
biopsy cores, rather than from sonomorphologic le-
sions. Because ultrasound technology continues to
progress, the introduction of methods, such as color
Doppler, power Doppler, and contrast-enhanced
techniques, means that Doppler-enhanced lesions
enable more information to be provided in target-
ing. Moreover, 3-D TRUS appears to be superior to
conventional 2-D TRUS in staging of prostate can-
cer, although further investigation is required to
verify this observation. The 10- to 12-core system-
atic random biopsy remains the mainstream strat-
egy in prostate biopsy. With the aid of a
nomogram, it is possible to obtain the optimal
number of biopsy cores while ensuring a 90% cer-
tainty of cancer detection.
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